Neuron Specific Enolase, S100-beta protein and progranulin as diagnostic biomarkers of status epilepticus.
Diagnosis
Etiology
Neuron Specific Enolase
Progranulin
S100-beta protein
Status epilepticus
Journal
Journal of neurology
ISSN: 1432-1459
Titre abrégé: J Neurol
Pays: Germany
ID NLM: 0423161
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
01
12
2021
accepted:
30
01
2022
revised:
29
01
2022
pubmed:
23
2
2022
medline:
25
6
2022
entrez:
22
2
2022
Statut:
ppublish
Résumé
Status epilepticus (SE) is a life-threatening prolonged epileptic seizure. A rapid diagnosis is fundamental to initiate antiepileptic treatment and to prevent the development of neurological sequels. Several serum and cerebrospinal fluid biomarkers have been proposed to help in the diagnosis of SE. Nevertheless, previous studies were conducted on too small patient cohorts, precluding the utilization of interesting biomarkers for the SE diagnosis. Here, we aimed to assess the ability of Neuron Specific Enolase (NSE), S100-beta protein (S100B) and progranulin to help in the diagnosis of SE in a large cohort of patients (36 control patients, 56 patients with pharmacoresistant epilepsy and 82 SE patients). Blood NSE, S100B and progranulin levels were higher in SE patients when compared with control patients or patients with pharmacoresistant epilepsy. Both NSE and progranulin levels were higher in cerebrospinal fluid from SE patients when compared with control patients. The receiver-operating characteristics curves revealed good accuracy at detecting SE for serum S100B (AUC 0.748) and plasma progranulin (AUC 0.756). The performances were lower for serum NSE (AUC 0.624). Eighty-four percent of patients with serum S100B levels above 0.09 ng/mL presented with a SE, whereas 90% of patients without SE had serum S100B levels lower than 0.09 ng/mL. Serum S100B levels were not significantly different according to SE etiology, SE semiology or SE refractoriness. Our results confirm that NSE, S100B and progranulin levels are increased after SE. We suggest that serum S100B levels might be added to clinical evaluation and electroencephalogram to identify difficult-to-diagnose form of SE.
Identifiants
pubmed: 35190890
doi: 10.1007/s00415-022-11004-2
pii: 10.1007/s00415-022-11004-2
doi:
Substances chimiques
Biomarkers
0
Progranulins
0
S100 Calcium Binding Protein beta Subunit
0
S100B protein, human
0
Phosphopyruvate Hydratase
EC 4.2.1.11
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3752-3760Subventions
Organisme : Agence Nationale de la Recherche
ID : ANR-10-IAIHU-06
Organisme : Fondation Recherche Médicale
ID : FDM20170839111
Organisme : Fondation Assitance Publique-Hôpitaux de Paris
ID : EPIRES- Marie Laure PLV Merchandising
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.
Références
Trinka E, Kälviäinen R (2017) 25 years of advances in the definition, classification and treatment of status epilepticus. Seizure 44:65–73. https://doi.org/10.1016/j.seizure.2016.11.001
doi: 10.1016/j.seizure.2016.11.001
pubmed: 27890484
Alkhachroum A, Der-Nigoghossian CA, Rubinos C, Claassen J (2020) Markers in status epilepticus prognosis. J Clin Neurophysiol 37:422–428. https://doi.org/10.1097/WNP.0000000000000761
doi: 10.1097/WNP.0000000000000761
pubmed: 32890064
pmcid: 7864547
Claassen J, Goldstein JN (2017) Emergency neurological life support: status epilepticus. Neurocrit Care 27:152–158. https://doi.org/10.1007/s12028-017-0460-1
doi: 10.1007/s12028-017-0460-1
pubmed: 28913605
Leitinger M, Beniczky S, Rohracher A et al (2015) Salzburg consensus criteria for non-convulsive status epilepticus—approach to clinical application. Epilepsy Behav 49:158–163. https://doi.org/10.1016/j.yebeh.2015.05.007
doi: 10.1016/j.yebeh.2015.05.007
pubmed: 26092326
Hanin A, Lambrecq V, Denis JA et al (2020) Cerebrospinal fluid and blood biomarkers of status epilepticus. Epilepsia 61:6–18. https://doi.org/10.1111/epi.16405
doi: 10.1111/epi.16405
pubmed: 31828792
Correale J, Rabinowicz AL, Heck CN et al (1998) Status epilepticus increases CSF levels of neuron-specific enolase and alters the blood-brain barrier. Neurology 50:1388–1391
doi: 10.1212/WNL.50.5.1388
DeGiorgio CM, Correale JD, Gott PS et al (1995) Serum neuron-specific enolase in human status epilepticus. Neurology 45:1134–1137
doi: 10.1212/WNL.45.6.1134
DeGiorgio CM, Heck CN, Rabinowicz AL et al (1999) Serum neuron-specific enolase in the major subtypes of status epilepticus. Neurology 52:746–749
doi: 10.1212/WNL.52.4.746
Gnanapavan S, Hegen H, Khalil M et al (2014) Guidelines for uniform reporting of body fluid biomarker studies in neurologic disorders. Neurology 83:1210–1216. https://doi.org/10.1212/WNL.0000000000000809
doi: 10.1212/WNL.0000000000000809
pubmed: 25150289
Vizuete AFK, Hennemann MM, Gonçalves CA, de Oliveira DL (2017) Phase-dependent astroglial alterations in li-pilocarpine-induced status epilepticus in young rats. Neurochem Res 42:2730–2742. https://doi.org/10.1007/s11064-017-2276-y
doi: 10.1007/s11064-017-2276-y
pubmed: 28444637
Freund Y, Bloom B, Bokobza J et al (2015) Predictive value of S100-B and copeptin for outcomes following seizure: the BISTRO International Cohort Study. PLoS ONE 10:e0122405. https://doi.org/10.1371/journal.pone.0122405
doi: 10.1371/journal.pone.0122405
pubmed: 25849778
pmcid: 4388444
Asadollahi M, Simani L (2019) The diagnostic value of serum UCHL-1 and S100-B levels in differentiate epileptic seizures from psychogenic attacks. Brain Res 1704:11–15. https://doi.org/10.1016/j.brainres.2018.09.028
doi: 10.1016/j.brainres.2018.09.028
pubmed: 30253122
Zhu S, Tai C, Petkau TL et al (2013) Progranulin promotes activation of microglia/macrophage after pilocarpine-induced status epilepticus. Brain Res 1530:54–65. https://doi.org/10.1016/j.brainres.2013.07.023
doi: 10.1016/j.brainres.2013.07.023
pubmed: 23887054
Huchtemann T, Körtvélyessy P, Feistner H et al (2015) Progranulin levels in status epilepticus as a marker of neuronal recovery and neuroprotection. Epilepsy Behav 49:170–172. https://doi.org/10.1016/j.yebeh.2015.06.022
doi: 10.1016/j.yebeh.2015.06.022
pubmed: 26211941
Cuschieri S (2019) The STROBE guidelines. Saudi J Anaesth 13:S31–S34. https://doi.org/10.4103/sja.SJA_543_18
doi: 10.4103/sja.SJA_543_18
pubmed: 30930717
pmcid: 6398292
Chou SH-Y, Macdonald RL, Keller E, Unruptured Intracranial Aneurysms, SAH CDE Project Investigators (2019) Biospecimens and molecular and cellular biomarkers in aneurysmal subarachnoid hemorrhage studies: common data elements and standard reporting recommendations. Neurocrit Care 30:46–59. https://doi.org/10.1007/s12028-019-00725-4
doi: 10.1007/s12028-019-00725-4
pubmed: 31144274
pmcid: 7888262
Helbok R, Beer R (2017) Cerebrospinal fluid and brain extracellular fluid in severe brain trauma. Handb Clin Neurol 146:237–258. https://doi.org/10.1016/B978-0-12-804279-3.00014-9
doi: 10.1016/B978-0-12-804279-3.00014-9
pubmed: 29110773
Trinka E, Cock H, Hesdorffer D et al (2015) A definition and classification of status epilepticus—report of the ILAE Task Force on classification of status epilepticus. Epilepsia 56:1515–1523. https://doi.org/10.1111/epi.13121
doi: 10.1111/epi.13121
pubmed: 26336950
Hirsch LJ, Gaspard N, van Baalen A et al (2018) Proposed consensus definitions for new-onset refractory status epilepticus (NORSE), febrile infection-related epilepsy syndrome (FIRES), and related conditions. Epilepsia 59:739–744. https://doi.org/10.1111/epi.14016
doi: 10.1111/epi.14016
pubmed: 29399791
Fluss R, Faraggi D, Reiser B (2005) Estimation of the Youden Index and its associated cutoff point. Biom J 47:458–472. https://doi.org/10.1002/bimj.200410135
doi: 10.1002/bimj.200410135
pubmed: 16161804
Chou SH-Y, Robertson CS, Participants in the International Multi-disciplinary Consensus Conference on the Multimodality Monitoring (2014) Monitoring biomarkers of cellular injury and death in acute brain injury. Neurocrit Care 21(Suppl 2):S187-214. https://doi.org/10.1007/s12028-014-0039-z
doi: 10.1007/s12028-014-0039-z
pubmed: 25208676
pmcid: 7888263
Tawk RG, Grewal SS, Heckman MG et al (2016) The relationship between serum neuron-specific enolase levels and severity of bleeding and functional outcomes in patients with nontraumatic subarachnoid hemorrhage. Neurosurgery 78:487–491. https://doi.org/10.1227/NEU.0000000000001140
doi: 10.1227/NEU.0000000000001140
pubmed: 26606669
Hanin A, Demeret S, Denis JA et al (2021) Serum neuron-specific enolase: a new tool for seizure risk monitoring after status epilepticus. Eur J Neurol. https://doi.org/10.1111/ene.15154
doi: 10.1111/ene.15154
pubmed: 34687105
Jaitly R, Sgro JA, Towne AR et al (1997) Prognostic value of EEG monitoring after status epilepticus: a prospective adult study. J Clin Neurophysiol 14:326–334
doi: 10.1097/00004691-199707000-00005
Sanchez-Peña P, Pereira A-R, Sourour N-A et al (2008) S100B as an additional prognostic marker in subarachnoid aneurysmal hemorrhage. Crit Care Med 36:2267–2273. https://doi.org/10.1097/CCM.0b013e3181809750
doi: 10.1097/CCM.0b013e3181809750
pubmed: 18596638
Tan TH-L, Perucca P, O’Brien TJ et al (2021) Inflammation, ictogenesis, and epileptogenesis: an exploration through human disease. Epilepsia 62:303–324. https://doi.org/10.1111/epi.16788
doi: 10.1111/epi.16788
pubmed: 33316111
Abboud H, Probasco JC, Irani S et al (2021) Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. J Neurol Neurosurg Psychiatry. https://doi.org/10.1136/jnnp-2020-325300
doi: 10.1136/jnnp-2020-325300
pubmed: 33649022